Novo’s revenue exceeded Wall Street expectations, but it forecast slower sales growth in 2025, partly due to increasing competition. Its rivals have also cut prices and expanded offerings to ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it ... plans that don’t cover obesity medicines. The list price for one month’s supply of Wegovy is $1,349.

Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), slashing the price of the drug for cash-paying patients without insurance ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket. The deal is available through the drugmaker's new NovoCare Pharmacy ...

The NovoCare rollout and Wegovy price cut follow similar moves by Novo's chief rival in the obesity market, Eli Lilly. Last month, Lilly cut the price of its Zepbound for self-paying patients ...

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...

In the midst of tariffs threatened by the US and counter-tariffs by other countries, Danish healthcare company Novo Nordisk’s top management has cautioned of possible price increases and ...

As part of its ongoing efforts to ensure patients who need Wegovy, or semaglutide, injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access it, Novo Nordisk (NVO) launched NovoCare Pharmacy ...

Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk said Wednesday it would cut the price of its popular weight-loss drug Wegovy for ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering ... or are on insurance plans that don’t cover obesity medicines. The list price for one month’s supply of Wegovy is ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with Eli Lilly (LLY) as a key rival. The company launched ...